ethyl 2-methyl-2-(3-{2-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate | 909112-29-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: ethyl 2-methyl-2-(3-{2-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate
• 英文别名: Ethyl 2-methyl-2-[3-[2-[[2-methyl-3,5-dioxo-4-(4,4,4-trifluorobutyl)-1,2,4-triazin-6-yl]oxy]ethyl]phenoxy]propanoate
• CAS: 909112-29-4
• 化学式: C₂₂H₂₈F₃N₃O₆
• 分子量: 487.476
• InChiKey: YMGOKQCJHJMVQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  34
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  97.7
• 氢给体数：
  0
• 氢受体数：
  10

文献信息

• 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy
  申请人：Dupont-Passelaigue Elisabeth

  公开号：US20080167313A1

  公开（公告）日：2008-07-10

  The invention concerns 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula (I), wherein: R 1 and R 2 , identical or different, represent a branched or linear C 1 -C 7 alkyl or alkenyl radical, a C 1 -C 6 alkyl radical substituted by groups such as trifluoromethyl, C 5 -C 6 cycloalkyl, nitrile, C 1 -C 4 alkoxycarbonylvinyl, hydroxycarbonylvinyl, C 1 -C 4 alkoxycarbonyl, carboxylate, benzyloxy or phenyl (for which the phenyl ring is optionally substituted by one or more groups such as C 1 -C 4 alkoyl, C 1 -C 4 alkoxy, nitro, halogen, trifluoromethyl); YR 3 represents oxygen or NR 3 for which R 3 represents hydrogen, a linear or branched C 1 -C 7 alkyl or alkenyl radical, a C 1 -C 6 alkyl radical substituted by groups such as trifluoromethyl or phenyl (for which the phenyl ring is optionally substituted by one or more groups such as C 1 -C 4 alkoyl, C 1 -C 4 alkoxy, nitro, halogen, trifluoromethyl); Z represents an oxygen atom or a carbon atom capable of being bound to the ortho, meta or para positions of the phenyl group of formula I; n can be 0 to 5 when Z=C or 2 to 4 when Z=O; X represents oxygen or sulphur; R 4 , R 5 , R 6 , R 7 and R 8 represent hydrogen or fluorine; R 9 , R 10 and R 11 represent hydrogen or a linear or branched C 1 -C 5 alkyl group as well as the pharmaceutically acceptable base addition salts, and the various enantiomers of compounds having asymmetric carbons, and their mixtures in all proportions including in particular the racemic mixtures.

  该发明涉及一般式（I）的3,5-二氧代-(2H,4H)-1,2,4-三嗪衍生物，其中：R1和R2，相同或不同，代表分支或直链的C1-C7烷基或烯基基团，被三氟甲基、C5-C6环烷基、腈基、C1-C4烷氧羰基乙烯基、羟基羰基乙烯基、C1-C4烷氧羰基、羧酸酯、苄氧基或苯基等基团取代的C1-C6烷基基团（其中苯环可选择地被一个或多个基团如C1-C4烷酰基、C1-C4烷氧基、硝基、卤素、三氟甲基取代）；YR3代表氧或NR3，其中R3代表氢、直链或分支的C1-C7烷基或烯基基团，被三氟甲基或苯基等基团取代的C1-C6烷基基团（其中苯环可选择地被一个或多个基团如C1-C4烷酰基、C1-C4烷氧基、硝基、卤素、三氟甲基取代）；Z代表一氧原子或一碳原子，能够与一般式I的苯基的邻位、间位或对位结合；当Z=C时，n可以为0至5，当Z=O时，n可以为2至4；X代表氧或硫；R4、R5、R6、R7和R8代表氢或氟；R9、R10和R11代表氢或直链或分支的C1-C5烷基基团，以及药学上可接受的碱盐，以及具有不对称碳的化合物的各种对映体以及它们在所有比例中的混合物，包括特别是消旋混合物。
• DERIVES DE 1 ,2,4-TRIAZINES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE HUMAINE
  申请人：PIERRE FABRE MEDICAMENT

  公开号：EP1856065B1

  公开（公告）日：2009-11-11
• US7713971B2
  申请人：——

  公开号：US7713971B2

  公开（公告）日：2010-05-11